138 related articles for article (PubMed ID: 38493911)
1. CRABP2 reduces the sensitivity of Olaparib in ovarian cancer by downregulating Caspase-8 and decreasing the production of reactive oxygen species.
Zeng S; Xu Z; Liu Y; Zhou S; Yan Y
Chem Biol Interact; 2024 Apr; 393():110958. PubMed ID: 38493911
[TBL] [Abstract][Full Text] [Related]
2. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
3. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
[TBL] [Abstract][Full Text] [Related]
5. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
[TBL] [Abstract][Full Text] [Related]
6. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
7. Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines.
Gralewska P; Gajek A; Marczak A; Rogalska A
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638899
[TBL] [Abstract][Full Text] [Related]
8. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
10. Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer.
Tang S; Shen Y; Wei X; Shen Z; Lu W; Xu J
Cell Death Dis; 2022 Sep; 13(9):826. PubMed ID: 36163324
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
13. Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
Shim JI; Ryu JY; Jeong SY; Cho YJ; Choi JJ; Hwang JR; Choi JY; Sa JK; Lee JW
Gynecol Oncol; 2022 May; 165(2):270-280. PubMed ID: 35305818
[TBL] [Abstract][Full Text] [Related]
14. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Han C; McNamara B; Bellone S; Harold J; Manara P; Hartwich TMP; Mutlu L; Yang-Hartwich Y; Zipponi M; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Mar; 170():172-178. PubMed ID: 36706643
[TBL] [Abstract][Full Text] [Related]
15. Olaparib for the treatment of ovarian cancer.
Bornstein E; Jimeno A
Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
[TBL] [Abstract][Full Text] [Related]
18. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
19. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
Bizzaro F; Fuso Nerini I; Taylor MA; Anastasia A; Russo M; Damia G; Guffanti F; Guana F; Ostano P; Minoli L; Hattersley MM; Arnold S; Ramos-Montoya A; Williamson SC; Galbiati A; Urosevic J; Leo E; Cavallaro U; Ghilardi C; Barry ST; Bani MR; Giavazzi R
J Hematol Oncol; 2021 Nov; 14(1):186. PubMed ID: 34742344
[TBL] [Abstract][Full Text] [Related]
20. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
Chen Y; Du H
Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
